New risk calculator could change the aspirin, statins, and blood pressure medications some people take

first_img What’s included? GET STARTED New risk calculator could change the aspirin, statins, and blood pressure medications some people take By Elizabeth Cooney June 4, 2018 Reprints General Assignment Reporter Liz focuses on cancer, biomedical engineering, and how patients feel the effects of Covid-19. Elizabeth Cooney What is it? Health @cooney_liz About the Author Reprintscenter_img APStock More than 11 million people may need to reconsider taking medications to avoid heart attack and stroke, according to new research that says current guidelines overestimate risk for some people, but underestimate risk for others, especially African-Americans.Right now, doctors can consult a calculator found online or in electronic health records to decide whether patients might benefit from aspirin, statins, or blood pressure medications. Those estimates of 10-year risk for cardiovascular disease were derived in 2013 and endorsed by the American College of Cardiology and the American Heart Association. They were based on statistical analyses that combined data from large studies such as the original Framingham Heart Study, whose participants were 30 to 62 years old in 1948. Unlock this article by subscribing to STAT+ and enjoy your first 30 days free! GET STARTED Log In | Learn More [email protected] Daily reporting and analysis The most comprehensive industry coverage from a powerhouse team of reporters Subscriber-only newsletters Daily newsletters to brief you on the most important industry news of the day STAT+ Conversations Weekly opportunities to engage with our reporters and leading industry experts in live video conversations Exclusive industry events Premium access to subscriber-only networking events around the country The best reporters in the industry The most trusted and well-connected newsroom in the health care industry And much more Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr. STAT+ is STAT’s premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond. Tags cardiologypatientslast_img read more